Literature DB >> 25482182

Gene therapy for Parkinson's disease: still a hot topic?

Jeffrey H Kordower1.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 25482182      PMCID: PMC4262915          DOI: 10.1038/npp.2014.235

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  6 in total

1.  Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

Authors:  William J Marks; Raymond T Bartus; Joao Siffert; Charles S Davis; Andres Lozano; Nicholas Boulis; Jerrold Vitek; Mark Stacy; Dennis Turner; Leonard Verhagen; Roy Bakay; Raymond Watts; Barton Guthrie; Joseph Jankovic; Richard Simpson; Michele Tagliati; Ron Alterman; Matthew Stern; Gordon Baltuch; Philip A Starr; Paul S Larson; Jill L Ostrem; John Nutt; Karl Kieburtz; Jeffrey H Kordower; C Warren Olanow
Journal:  Lancet Neurol       Date:  2010-10-20       Impact factor: 44.182

2.  Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.

Authors:  Jeffrey H Kordower; C Warren Olanow; Hemraj B Dodiya; Yaping Chu; Thomas G Beach; Charles H Adler; Glenda M Halliday; Raymond T Bartus
Journal:  Brain       Date:  2013-08       Impact factor: 13.501

3.  Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.

Authors:  Gabriele Mittermeyer; Chadwick W Christine; Kathryn H Rosenbluth; Suzanne L Baker; Philip Starr; Paul Larson; Paul L Kaplan; John Forsayeth; Michael J Aminoff; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-04-10       Impact factor: 5.695

4.  Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Authors:  Stéphane Palfi; Jean Marc Gurruchaga; G Scott Ralph; Helene Lepetit; Sonia Lavisse; Philip C Buttery; Colin Watts; James Miskin; Michelle Kelleher; Sarah Deeley; Hirokazu Iwamuro; Jean Pascal Lefaucheur; Claire Thiriez; Gilles Fenelon; Cherry Lucas; Pierre Brugières; Inanna Gabriel; Kou Abhay; Xavier Drouot; Naoki Tani; Aurelie Kas; Bijan Ghaleh; Philippe Le Corvoisier; Patrice Dolphin; David P Breen; Sarah Mason; Natalie Valle Guzman; Nicholas D Mazarakis; Pippa A Radcliffe; Richard Harrop; Susan M Kingsman; Olivier Rascol; Stuart Naylor; Roger A Barker; Philippe Hantraye; Philippe Remy; Pierre Cesaro; Kyriacos A Mitrophanous
Journal:  Lancet       Date:  2014-01-10       Impact factor: 79.321

5.  AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

Authors:  Peter A LeWitt; Ali R Rezai; Maureen A Leehey; Steven G Ojemann; Alice W Flaherty; Emad N Eskandar; Sandra K Kostyk; Karen Thomas; Atom Sarkar; Mustafa S Siddiqui; Stephen B Tatter; Jason M Schwalb; Kathleen L Poston; Jaimie M Henderson; Roger M Kurlan; Irene H Richard; Lori Van Meter; Christine V Sapan; Matthew J During; Michael G Kaplitt; Andrew Feigin
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

Review 6.  Trophic factor gene therapy for Parkinson's disease.

Authors:  Jeffrey H Kordower; Anders Bjorklund
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

  6 in total
  1 in total

Review 1.  Repairing the Brain: Gene Therapy.

Authors:  Tomas Björklund
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.